DE602005024704D1 - Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür - Google Patents

Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Info

Publication number
DE602005024704D1
DE602005024704D1 DE602005024704T DE602005024704T DE602005024704D1 DE 602005024704 D1 DE602005024704 D1 DE 602005024704D1 DE 602005024704 T DE602005024704 T DE 602005024704T DE 602005024704 T DE602005024704 T DE 602005024704T DE 602005024704 D1 DE602005024704 D1 DE 602005024704D1
Authority
DE
Germany
Prior art keywords
atp channel
targeting
therapeutic agents
method therefor
use method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005024704T
Other languages
English (en)
Inventor
Marc J Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
US Department of Veterans Affairs VA
Original Assignee
University of Maryland at Baltimore
US Department of Veterans Affairs VA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore, US Department of Veterans Affairs VA filed Critical University of Maryland at Baltimore
Publication of DE602005024704D1 publication Critical patent/DE602005024704D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602005024704T 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür Active DE602005024704D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61075804P 2004-09-18 2004-09-18
US69827205P 2005-07-11 2005-07-11
PCT/US2005/033194 WO2006034048A2 (en) 2004-09-18 2005-09-16 Therapeutic agents targeting the ncca-atp channel and methods of use thereof

Publications (1)

Publication Number Publication Date
DE602005024704D1 true DE602005024704D1 (de) 2010-12-23

Family

ID=36090529

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005024704T Active DE602005024704D1 (de) 2004-09-18 2005-09-16 Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür

Country Status (9)

Country Link
US (2) US7872048B2 (de)
EP (1) EP1799227B1 (de)
JP (2) JP5085326B2 (de)
AT (1) ATE487484T1 (de)
AU (1) AU2005287090A1 (de)
CA (1) CA2580606A1 (de)
DE (1) DE602005024704D1 (de)
IL (1) IL181826A0 (de)
WO (1) WO2006034048A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20030215889A1 (en) 2002-03-20 2003-11-20 Simard J. Marc Non-selective cation channel in neural cells and methods for treating brain swelling
CA2571718A1 (en) * 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of an acute injury to the central nervous system
WO2006000607A1 (es) * 2004-06-23 2006-01-05 Neurotec Pharma, S.L. Uso de activadores de los canales de katp (kco), en particular el diazóxido, en el tratamiento de la inflamación crónica de snc asociada a algunas efermedades
JP5307397B2 (ja) * 2004-09-18 2013-10-02 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする治療剤およびその使用方法
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
EP1884244A1 (de) * 2006-08-02 2008-02-06 Assistance Publique - Hopitaux de Paris Kalium-Kanal Liganden zur Behandlung von Diabetes und neuropsychologischen Störungen
US10004703B2 (en) 2006-10-12 2018-06-26 Biogen Chesapeake Llc Treatment of alzheimer's disease using compounds that reduce the activity of non-selective CA++ activated ATP-sensitive cation channels regulated by SUR1 channels
WO2008046014A1 (en) * 2006-10-12 2008-04-17 Remedy Pharmaceuticals, Inc. Treatment of alzheimer's disease using compounds that reduce the activity of non-selective ca++- activated atp-sensitive cation channels regulated by sur1 receptors
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
WO2008098160A1 (en) * 2007-02-09 2008-08-14 University Of Maryland, Baltimore Antagonists of a non-selective cation channel in neural cells
EP2167107B1 (de) 2007-06-22 2016-12-14 University of Maryland, Baltimore Inhibitoren von ncca-atp-kanälen zur therapie
PL2868315T3 (pl) 2007-12-04 2018-06-29 Biogen Chesapeake Llc Udoskonalone preparaty i sposoby liofilizacji oraz uzyskiwane liofilizaty
WO2009097443A2 (en) * 2008-01-29 2009-08-06 Remedy Pharmaceuticals, Inc. Liquid formulations of compounds active at sulfonylurea receptors
EP2326318A4 (de) * 2008-09-16 2012-05-23 Univ Maryland Sur1-hemmer für therapeutische zwecke
WO2012012347A2 (en) 2010-07-19 2012-01-26 Remedy Pharmaceuticals, Inc. Methods of intravenous administration of glyburide and other drugs
JP2012061053A (ja) 2010-09-14 2012-03-29 Yuuki Kitaoka 投薬装置、投薬装置の作動方法及び投薬方法
EP2609914A1 (de) 2011-12-29 2013-07-03 Universitätsklinikum Hamburg-Eppendorf Neue Verfahren zur Behandlung oder Vermeidung von Neurodegeneration
KR102200176B1 (ko) 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
EP3065729A4 (de) 2013-11-06 2017-05-31 Aeromics, Inc. Neuartige formulierungen

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5725A (en) 1848-08-22 Hydraulic ram
US871A (en) 1838-08-03 Mode of protectinc notes
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
GB8809205D0 (en) 1988-04-19 1988-05-25 Nye P C G Treatment of oedema
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5166162A (en) 1990-03-02 1992-11-24 Adir Et Compagnie Pyridylsulfonylurea and pyridylsulfonylthiourea compounds
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
CA2044853C (en) 1990-07-19 2004-11-09 Susan A. Greenfield Method for treating parkinson's disease employing an atp-sensitive potassium channel blocker
US5236932A (en) 1990-07-19 1993-08-17 E. R. Squibb & Sons, Inc. Method for treating Parkinson's disease employing quinine
US5215985A (en) 1990-07-20 1993-06-01 E. R. Squibb & Sons, Inc. Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker
US5811393A (en) 1990-10-16 1998-09-22 The Childrens Medical Center Corp. Heparin binding mitogen with homology to epidermal growth factor (EGF)
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5916871A (en) 1992-04-27 1999-06-29 Kansas State University Research Foundation Inhibitory factor
EP0641192B1 (de) 1992-05-18 1997-07-23 Minnesota Mining And Manufacturing Company Einrichtung zur transmucosalen wirkstoffabgabe
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
DE4430212A1 (de) 1994-08-28 1996-02-29 Merck Patent Gmbh Ortho-substituierte Benzoesäure-Derivate
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US20010003751A1 (en) 1995-02-22 2001-06-14 Terashita Zen-Ichi Pharmaceutical composition for treating transient ischemic attack
AUPN193095A0 (en) 1995-03-24 1995-04-27 Polychip Pharmaceuticals Pty Ltd Potassium ion channel blockers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5545656A (en) 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US7608262B2 (en) 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
US6184248B1 (en) 1996-09-05 2001-02-06 Robert K. K. Lee Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
EP1006798A4 (de) 1996-09-05 2003-03-05 Massachusetts Inst Technology Zusammensetzungen und verfahren zur behandlung neurologischer störungen und neurodegenerativer erkrankungen
US5962645A (en) 1996-10-04 1999-10-05 University Of Maryland Antiproliferative factor from patients with interstitial cystitis
AU8283898A (en) 1997-06-30 1999-01-25 University Of Maryland At Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
US6679859B1 (en) 1997-10-24 2004-01-20 Alliance Pharmaceutical Corp. Amelioration of ischemic damage using synthetic oxygen carriers
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU1690399A (en) 1997-12-26 1999-07-19 Mochida Pharmaceutical Co., Ltd. Neovascularization inhibitor containing dienogest as the active ingredient
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6100047A (en) 1999-04-07 2000-08-08 Zen Bio, Inc. Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
CA2328774A1 (en) 1998-04-17 1999-10-28 John Warren Method of treating interstitial cystitis with recombinant heparin-binding epidermal growth factor-like growth factor (hb-egf)
US6613785B2 (en) 1998-07-21 2003-09-02 Smithkline Beecham Plc Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
JP4777515B2 (ja) 1998-10-26 2011-09-21 エイブイアイ バイオファーマ， インコーポレイテッド ｐ５３モルホリノに基づくアンチセンス
EP2314700A1 (de) 1999-01-28 2011-04-27 Medical College of Georgia Research Institute, Inc Zusammensetzung und Verfahren zur in vivo und in vitro Abschwächung der Genexpression mittels dobbelsträngiger RNA
BR0009593A (pt) 1999-04-06 2002-06-18 Sankyo Co Agente melhorador de resistência à insulina, agente hipoglicêmico, agente imunorregulador, inibidor de aldose redutase, inibidor de 5-lipoxigenase, supressor de produção de lipìdios peroxidados, ativador de ppar, antagonista de leucotrienos, promotor de formação hidroxiadipocelular ou antagonista de cálcio, agente preventivo e/ou terapêutico, derivados de ácido carboxìlico, medicamento, composição farmacêutica, e, uso de um composto
EP1178963A1 (de) 1999-05-12 2002-02-13 Neurosearch A/S Ionenkanal modulierende mittel
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
SG149676A1 (en) 1999-12-23 2009-02-27 Novartis Ag Use of hypoglycemic agent for treating impaired glucose metabolism
AU2001234602A1 (en) 2000-01-26 2001-08-07 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
EP1145717B1 (de) 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistische Wirkung von Glyburide und Milrinone
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
AU2000278584B2 (en) 2000-05-15 2006-11-16 Smithkline Beecham Corporation Antithrombotic agents
US6627636B2 (en) 2000-06-15 2003-09-30 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6492339B1 (en) * 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
US20030171407A1 (en) 2002-03-07 2003-09-11 Upsher-Smith Laboratories, Inc. Composition for reducing blood glucose and cholesterol
US20030215889A1 (en) 2002-03-20 2003-11-20 Simard J. Marc Non-selective cation channel in neural cells and methods for treating brain swelling
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2571718A1 (en) 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of an acute injury to the central nervous system
JP5085326B2 (ja) * 2004-09-18 2012-11-28 ユニバーシティ オブ メリーランド，ボルチモア ＮＣＣａ−ＡＴＰチャネルを標的とする処置剤およびその使用方法
US20080248099A1 (en) 2005-11-11 2008-10-09 Ishii Douglas N Method for Treating Disease or Disorder of Adult Central Nervous System Associated with Tissue Shrinkage or Atrophy by Administration of Insulin
US9511075B2 (en) 2007-01-12 2016-12-06 The University Of Maryland, Baltimore Targeting NCCA-ATP channel for organ protection following ischemic episode
US7787809B2 (en) * 2007-09-10 2010-08-31 Kabushiki Kaisha Toshiba Image forming apparatus, transfer unit thereof, and method of shifting transfer rollers thereof

Also Published As

Publication number Publication date
WO2006034048A3 (en) 2008-01-17
US7872048B2 (en) 2011-01-18
EP1799227B1 (de) 2010-11-10
US20110092542A1 (en) 2011-04-21
CA2580606A1 (en) 2006-03-30
US20060100183A1 (en) 2006-05-11
IL181826A0 (en) 2008-04-13
JP5085326B2 (ja) 2012-11-28
WO2006034048A2 (en) 2006-03-30
JP2008513478A (ja) 2008-05-01
AU2005287090A1 (en) 2006-03-30
JP2012056966A (ja) 2012-03-22
EP1799227A4 (de) 2008-09-24
EP1799227A2 (de) 2007-06-27
ATE487484T1 (de) 2010-11-15
US8569377B2 (en) 2013-10-29
WO2006034048A8 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
DE602005024704D1 (de) Therapeutische mittel zum targeting des nc ca-atp-kanals und verwendungsverfahren dafür
DE602005024597D1 (de) Therapeutische mittel zum targeting des ncca-atp-kanals und verwendungsverfahren dafür
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
ATE435015T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
ES2340179T3 (es) Antagonistas de urea del receptor p2y1 utiles en el tratamiento de afecciones tromboticas.
ATE527251T1 (de) Bicyclische derivate als modulatoren von ionenkanälen
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
CY1109551T1 (el) Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
DK1583541T3 (da) Forbindelser og fremgangsmåder til at øge neurogenese
MA28279A1 (fr) Derives d&#39;indole et utilisation de ceux-ci comme inhibiteurs de kinase, notamment des inhibiteurs de ikk2
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
NO20065544L (no) Urea-antagonister av P2Y1-reseptor anvendbare i behandling av trombotiske tilstander.
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
BR0315689A (pt) Alvo para terapia de dano cognitivo
ATE423087T1 (de) Proteasome inhibitoren und deren verwendung
BRPI0414794A (pt) oxadiazolidinadionas substituìdas
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ATE288747T1 (de) Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
ATE540036T1 (de) Heterocyclische derivate als ionenkanalmodulatoren
MX2007010484A (es) Moleculas y metodos para usarlas para tratar enfermedades asociadas con mcp-1/ccr2.